Small-Cell Lung Cancer - Pipeline Review, H1 2018 | Pharmaceuticals Market Analysis & Trends 2018 | JSB Market Research
Summary
Small
cell lung cancer (SCLC) is
a fast-growing type of lung cancer. It spreads much more quickly than non-small
cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually
starts in the breathing tubes (bronchi) in the center of the chest. These
tumors often spread rapidly (metastasize) to other parts of the body, including
the brain, liver, and bone.
Symptoms
of SCLC: Bloody Sputum, Chest Pain, Cough, Loss
of Appetite, Weight Loss and Wheezing.
Treatment
includes: Surgery, Radiation Therapy, Chemotherapy
The latest Pharmaceutical and Healthcare
pipeline guide on Small-Cell Lung Cancer - Pipeline Review, H1 2018, provides
comprehensive information on the therapeutics under development for Small-Cell
Lung Cancer (Oncology), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest news and
press releases.
The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 47, 33, 2, 36 and 6 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 3 and 1 molecules, respectively.
Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Request a sample report: http://www.jsbmarketresearch.com/sample-request/small-cell-lung-cancer-pipeline-review-h1-2018
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
of Report:
ü The pipeline guide provides a snapshot of the
global therapeutic landscape of Small-Cell Lung Cancer (Oncology).
ü The pipeline guide reviews pipeline
therapeutics for Small-Cell Lung Cancer (Oncology) by companies and
universities/research institutes based on information derived from company and
industry-specific sources.
ü The pipeline guide covers pipeline products
based on several stages of development ranging from pre-registration till
discovery and undisclosed stages.
ü The pipeline guide features descriptive drug
profiles for the pipeline products which comprise, product description,
descriptive licensing and collaboration details, R&D brief, MoA & other
developmental activities.
ü The pipeline guide reviews key companies
involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all
their major and minor projects.
ü The pipeline guide evaluates Small-Cell Lung
Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target,
route of administration (RoA) and molecule type.
ü The pipeline guide encapsulates all the dormant
and discontinued pipeline projects.
ü The pipeline guide reviews latest news related
to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)
Reasons to buy
· Procure strategically important competitor information,
analysis, and insights to formulate effective R&D strategies.
· Recognize emerging players with potentially
strong product portfolio and create effective counter-strategies to gain
competitive advantage.
· Find and recognize significant and varied types
of therapeutics under development for Small-Cell Lung Cancer (Oncology).
· Classify potential new clients or partners in
the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
· Formulate corrective measures for pipeline
projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and
focus of Indication therapeutics.
· Develop and design in-licensing and
out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope.
· Adjust the therapeutic portfolio by recognizing
discontinued projects and understand from the know-how what drove them from
pipeline.
Related
Reports:
Non-Hodgkin
Lymphoma - Pipeline Review, H1 2018
Chronic
Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018
Spinal
Cord Stimulators - Medical Devices Pipeline Assessment, 2018
Interventional
Neurology Devices - Medical Devices Pipeline Assessment, 2018
Total
Artificial Heart - Medical Devices Pipeline Assessment, 2018
Pacemakers
- Medical Devices Pipeline Assessment, 2018
Cardiac
Assist Devices - Medical Devices Pipeline Assessment, 2018
Contact
Us:
+91-9987295242
Comments
Post a Comment